AbbVie Inc (ABBV)

ABBV (NYSE:Drugs)
$49.32
neg -0.82
-1.64%
Today's Range: 49.00 - 50.13 | ABBV Avg Daily Volume: 6,798,700
Last Update: 04/24/14 - 4:00 PM EDT
Volume: 6,628,678
YTD Performance: -5.06%
Open: $50.00
Previous Close: $50.14
52 Week Range: $40.10 - $54.78
Oustanding Shares: 1,588,518,764
Market Cap: 79,818,469,352
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 3 4 4
Moderate Buy 0 0 0 0
Hold 5 5 5 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.11 2.25 2.11 2.20
Latest Dividend: 0.42
Latest Dividend Yield: 3.16%
Dividend Ex-Date: 04/11/14
Price Earnings Ratio: 20.74
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
20.74 10.80 29.23
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.60% 11.08% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 5.40 0.00 0.00
Net Income 53.70 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ABBV:
EBITDA 6.97B
Revenue 18.38B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $0.68 $0.76 $3.12 $3.65
Number of Analysts 8 6 11 9
High Estimate $0.71 $0.81 $3.18 $3.93
Low Estimate $0.66 $0.72 $3.08 $3.40
Prior Year $0.68 $0.82 $3.14 $3.12
Growth Rate (Year over Year) 0.00% -7.11% -0.75% 16.98%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Chris Laudani

 | Apr 24, 2014 | 12:00 PM EDT

Investors may be worried about Sovaldi's price.

By

Jim Cramer

 | Apr 23, 2014 | 3:48 PM EDT

Its potent hepatitis C treatment is not a boon for shareholders.

By

Gary Dvorchak

 | Apr 9, 2014 | 12:30 PM EDT

The goal is always simply to get out where we got in.

bearishAbbVie price target lowered at Jefferies

Mar 19, 2014 | 7:33 AM EDT

ABBV cut its number, Jefferies said. Competitive data in Hep C, pay for delay litigation re Androgel. $60 price target. 

bearishAbbvie downgraded at Morgan Stanley

Dec 19, 2013 | 7:48 AM EST

ABBV was downgraded from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $57 price target. 

bullishAbbvie added to Conviction Buy List at Goldman

Dec 3, 2013 | 8:11 AM EST

ABBV was placed on the Conviction Buy list, according to Goldman Sachs. Company has an attractive pipeline, with multiple potential catalysts. $60 price target. 

bullishAbbvie upgraded at BMO

Oct 28, 2013 | 8:05 AM EDT

ABBV was upgraded from Market Perform to Outperform, BMO Capital said. $55 price target. Humira can drive impressive growth over the coming quarters. 

By

Meena Krishnamsetty

 | Aug 22, 2013 | 11:30 AM EDT

Here's what Glen Dubin's Highbridge funds have been buying.

By

Sham Gad

 | Aug 19, 2013 | 2:00 PM EDT

They can spend a lot of time analyzing their picks.

bullishAbbvie estimates, target upped at BMO

Jul 29, 2013 | 8:18 AM EDT

ABBV estimates were boosted through 2014, BMO Capital said. Company's pipeline is advancing and guidance appears beatable. Market Perform rating and new $48 price target. 

CH Robinson has had a higher gap opening the last four days in a row. Boy, someone really ...
The wicked, whipsaw action following FB's earnings release last evening warns me the stock...
This stock has been a dog for years, but its ears are perking here lately, and today has m...
Good afternoon! Oil has taken a swift turn this week and is showing further weakness ahead...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.